Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.66 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.64 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.64 |
| ▸ | LTA4H | P09960 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679020 | 0.91 | HRH3 (0.67) | HRH3KEAP1NFE2L2LTA4HKDM4E | |
| SCHEMBL13781502 | 0.80 | HRH3 (0.68) | HRH3KEAP1NFE2L2LTA4HKDM4E | |
| SCHEMBL1908631 | 0.79 | LTA4H (0.50) | LTA4HKDM4EPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL8430078 | 0.79 | HRH3 (0.72) | HRH3KEAP1NFE2L2LTA4HKDM4E | |
| SCHEMBL9972846 | 0.79 | ESR1 (0.47) | HRH3KEAP1NFE2L2ALDH1A1SMN1; SMN2 | |
| SCHEMBL13652493 | 0.79 | LMNA (0.55) | LTA4HKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL678570 | 0.78 | HRH3 (0.56) | HRH3LTA4HKDM4E | |
| SCHEMBL4607528 | 0.78 | HRH3 (0.70) | HRH3KEAP1NFE2L2LTA4HKDM4E | |
| SCHEMBL14608491 | 0.78 | HRH3 (0.70) | HRH3KEAP1NFE2L2LTA4HKDM4E | |
| SCHEMBL185585 | 0.78 | HRH3 (0.70) | HRH3KEAP1NFE2L2LTA4HKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957075-B2 | O-GlcNAc transferase inhibitors and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-02-17 | — | — | US | disclosed |
| US-20120108605-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108605-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | OGA, OGT, UGGT1 | HRH3 4616/4885KEAP1 392/4885NFE2L2 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.